See more : Standard Uranium Ltd. (STND.V) Income Statement Analysis – Financial Results
Complete financial analysis of Dr. Reddy’s Laboratories Limited (RDY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dr. Reddy’s Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nidec Chaun-Choung Technology Corporation (6230.TW) Income Statement Analysis – Financial Results
- Electra Battery Materials Corporation (ELBM) Income Statement Analysis – Financial Results
- Cogna Educação S.A. (COGNY) Income Statement Analysis – Financial Results
- ARC Finance Limited (ARCFIN.BO) Income Statement Analysis – Financial Results
- Uni-President China Holdings Ltd (0220.HK) Income Statement Analysis – Financial Results
Dr. Reddy's Laboratories Limited (RDY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.drreddys.com
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 279.16B | 245.88B | 214.39B | 189.72B | 174.60B | 153.85B | 142.03B | 140.81B | 154.71B | 148.19B | 132.17B | 116.27B | 96.74B | 74.69B | 70.28B | 69.44B | 50.01B | 65.25B | 24.33B | 19.47B | 20.12B | 18.02B | 16.60B | 10.94B |
| Cost of Revenue | 115.56B | 42.91B | 100.55B | 86.65B | 80.59B | 70.42B | 65.72B | 62.45B | 62.43B | 62.79B | 56.37B | 55.69B | 43.43B | 34.43B | 33.94B | 32.94B | 24.60B | 34.30B | 12.45B | 9.39B | 9.37B | 7.82B | 6.86B | 5.72B |
| Gross Profit | 163.61B | 202.97B | 113.84B | 103.08B | 94.01B | 83.43B | 76.30B | 78.36B | 92.28B | 85.40B | 75.80B | 60.58B | 53.31B | 40.26B | 36.34B | 36.50B | 25.41B | 30.95B | 11.88B | 10.09B | 10.76B | 10.20B | 9.74B | 5.22B |
| Gross Profit Ratio | 58.61% | 82.55% | 53.10% | 54.33% | 53.84% | 54.23% | 53.72% | 55.65% | 59.65% | 57.63% | 57.35% | 52.10% | 55.10% | 53.90% | 51.71% | 52.56% | 50.81% | 47.43% | 48.83% | 51.80% | 53.46% | 56.62% | 58.68% | 47.74% |
| Research & Development | 22.87B | 19.38B | 17.48B | 16.54B | 15.41B | 15.61B | 18.27B | 19.55B | 17.83B | 17.45B | 12.40B | 7.67B | 5.91B | 5.06B | 3.79B | 4.04B | 3.53B | 2.47B | 2.16B | 2.80B | 2.00B | 1.37B | 740.85M | 506.99M |
| General & Administrative | 0.00 | 46.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 59.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.20B | 105.93B | 62.08B | 54.56B | 50.13B | 48.89B | 46.91B | 46.37B | 45.70B | 42.59B | 38.78B | 33.58B | 28.87B | 23.69B | 22.51B | 21.02B | 15.18B | 14.08B | 8.05B | 6.81B | 6.58B | 5.01B | 3.66B | 2.81B |
| Other Expenses | -4.20B | -7.70B | -2.76B | -982.00M | -4.29B | -691.00M | -843.00M | -1.15B | -986.00M | -1.06B | -1.36B | -2.34B | -784.00M | -1.12B | -569.00M | 254.00M | 3.34B | 3.14B | 226.45M | 838.82M | 100.65M | 488.15M | 278.38M | 418.71M |
| Operating Expenses | 95.88B | 117.62B | 76.80B | 70.12B | 61.25B | 62.54B | 64.39B | 64.86B | 62.66B | 59.12B | 49.77B | 38.78B | 34.01B | 27.64B | 25.73B | 25.31B | 22.05B | 19.70B | 10.43B | 10.45B | 8.67B | 6.86B | 4.68B | 3.73B |
| Cost & Expenses | 211.44B | 160.52B | 177.35B | 156.76B | 141.84B | 132.96B | 130.11B | 127.31B | 125.09B | 121.90B | 106.14B | 94.47B | 77.45B | 62.07B | 59.67B | 58.25B | 46.65B | 54.00B | 22.88B | 19.84B | 18.04B | 14.68B | 11.54B | 9.45B |
| Interest Income | 2.28B | 1.18B | 3.08B | 2.62B | 888.00M | 2.28B | 540.00M | 558.00M | 1.40B | 1.06B | 1.09B | 900.00M | 377.00M | 173.00M | 369.00M | 482.00M | 1.60B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71B | 1.43B | 958.00M | 970.00M | 983.00M | 1.16B | 788.00M | 634.00M | 826.00M | 1.09B | 1.27B | 1.02B | 1.07B | 362.00M | 372.00M | 1.67B | 1.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.84B | 12.64B | 11.82B | 12.80B | 12.47B | 12.19B | 11.71B | 11.28B | 10.25B | 8.10B | 7.11B | 5.55B | 5.21B | 4.15B | 4.16B | 3.81B | 6.20B | 3.02B | 1.57B | 1.31B | 1.13B | 1.01B | 945.26M | 892.60M |
| EBITDA | 88.42B | 74.43B | 47.74B | 45.71B | 41.79B | 31.87B | 23.74B | 24.55B | 40.18B | 35.16B | 33.14B | 22.49B | 20.33B | 16.82B | 6.59B | 1.49B | 7.31B | 14.27B | 2.71B | 1.02B | 2.83B | 4.35B | 6.01B | 2.38B |
| EBITDA Ratio | 31.67% | 44.24% | 24.55% | 25.75% | 28.37% | 15.34% | 8.39% | 9.59% | 19.15% | 17.74% | 19.70% | 19.34% | 21.02% | 16.90% | 21.61% | 22.33% | 16.79% | 23.67% | 11.13% | 4.24% | 14.09% | 22.62% | 33.95% | 21.17% |
| Operating Income | 67.73B | 96.28B | 40.82B | 36.06B | 37.06B | 20.89B | 11.92B | 13.50B | 29.62B | 26.29B | 26.03B | 21.11B | 18.25B | 12.63B | 2.01B | -2.83B | 3.36B | 11.25B | 1.45B | -366.46M | 2.08B | 3.34B | 5.06B | 1.49B |
| Operating Income Ratio | 24.26% | 39.16% | 19.04% | 19.01% | 21.22% | 13.58% | 8.39% | 9.59% | 19.15% | 17.74% | 19.70% | 18.16% | 18.87% | 16.91% | 2.86% | -4.08% | 6.71% | 17.24% | 5.94% | -1.88% | 10.36% | 18.52% | 30.47% | 13.59% |
| Total Other Income/Expenses | 4.14B | 3.34B | 2.82B | 4.04B | 2.04B | 1.56B | 2.42B | 1.16B | -2.48B | 1.88B | 574.00M | 1.41B | 214.00M | -186.00M | -7.99B | -15.44B | -493.72M | -725.88M | 446.53M | 107.40M | 465.35M | 572.90M | 9.11M | -426.12M |
| Income Before Tax | 71.87B | 60.49B | 32.30B | 28.32B | 18.03B | 22.44B | 14.34B | 14.65B | 27.14B | 28.16B | 26.61B | 21.68B | 18.47B | 12.44B | 2.05B | -4.00B | 3.44B | 10.53B | 1.89B | 107.03M | 2.55B | 3.92B | 5.07B | 1.06B |
| Income Before Tax Ratio | 25.74% | 24.60% | 15.06% | 14.93% | 10.33% | 14.59% | 10.10% | 10.41% | 17.54% | 19.00% | 20.13% | 18.64% | 19.09% | 16.66% | 2.92% | -5.75% | 6.88% | 16.13% | 7.78% | 0.55% | 12.65% | 21.75% | 30.53% | 9.69% |
| Income Tax Expense | 16.19B | 15.41B | 8.73B | 9.18B | -1.47B | 3.65B | 4.54B | 2.61B | 7.13B | 5.98B | 5.09B | 4.90B | 4.20B | 1.40B | 985.00M | 1.17B | -1.23B | 1.18B | 259.07M | -94.28M | 69.41M | 396.92M | 153.68M | 320.24M |
| Net Income | 55.68B | 45.07B | 23.57B | 17.24B | 19.50B | 18.80B | 9.81B | 12.04B | 20.01B | 22.18B | 21.51B | 16.78B | 14.26B | 11.04B | 1.07B | -5.17B | 4.68B | 9.35B | 1.63B | 211.27M | 2.48B | 3.52B | 4.92B | 739.28M |
| Net Income Ratio | 19.95% | 18.33% | 10.99% | 9.09% | 11.17% | 12.22% | 6.90% | 8.55% | 12.94% | 14.97% | 16.28% | 14.43% | 14.74% | 14.78% | 1.52% | -7.44% | 9.36% | 14.33% | 6.71% | 1.08% | 12.32% | 19.55% | 29.60% | 6.76% |
| EPS | 334.02 | 271.47 | 142.08 | 103.94 | 117.62 | 113.28 | 59.13 | 72.24 | 117.34 | 130.22 | 126.52 | 98.82 | 84.16 | 65.28 | 6.33 | -30.70 | 22.88 | 58.46 | 10.64 | 1.38 | 15.79 | 23.05 | 32.33 | 5.85 |
| EPS Diluted | 334.02 | 270.90 | 141.69 | 103.65 | 117.40 | 113.09 | 59.01 | 72.09 | 116.98 | 129.75 | 126.04 | 98.44 | 83.81 | 64.95 | 6.30 | -30.70 | 22.80 | 58.21 | 10.62 | 1.38 | 15.78 | 23.05 | 32.27 | 5.85 |
| Weighted Avg Shares Out | 166.71M | 166.03M | 165.88M | 165.84M | 165.76M | 165.92M | 165.85M | 166.65M | 170.55M | 170.31M | 170.04M | 169.78M | 169.47M | 169.13M | 168.71M | 168.35M | 168.08M | 158.55M | 153.09M | 153.04M | 153.03M | 153.03M | 152.06M | 126.36M |
| Weighted Avg Shares Out (Dil) | 166.71M | 166.38M | 166.34M | 166.32M | 166.08M | 166.20M | 166.19M | 167.00M | 171.07M | 170.93M | 170.70M | 170.43M | 170.18M | 169.97M | 169.62M | 168.35M | 168.69M | 159.26M | 153.40M | 153.12M | 153.10M | 153.03M | 152.30M | 126.36M |
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Q2 & H1FY25 Financial Results
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
Source: https://incomestatements.info
Category: Stock Reports